Shengmai injection, consisting of Panax ginseng, Radix ophiopogonis and Schisandra chinensis, is a widely used Chinese medicine for the treatment of various cardiovascular diseases. In this study, tissue distribution and excretion of its multiple active components including protopanaxatriol-type (Ppt-type) ginsenosides (ginsenoside Rg1, Re, Rf and Rg2), protopanaxadiol-type (Ppd-type) ginsenosides (ginsenoside Rb1, Rd and Rc), ophiopogonin (ophiopogonin D), and lignan (schisandrin, schisandrol B and schizandrin B) in rat after single intravenous administration of Shengmai injection were reported. Ppt-type ginsenosides exhibited quick and wide distribution from blood into tissues and were eliminated rapidly through biliary, urinary and fecal excretions. Ppd-type ginsenosides Rb1, Rd and Rc distributed quickly from blood to all tissues but exhibited slow elimination by biliary and urinary excretions. Ophiopogonin D was excreted into bile with no urinary and fecal excretion, indicating its elimination in the form of secondary metabolites. Schisandrin, schisandrol B and schizandrin B was found to distribute quickly from blood into most tissues and had accumulation in these tissues. Very low biliary, urinary and fecal excretion implied that lignan was mainly excreted in the form of their metabolites. This study produced a first hand in vivo tissue distribution and dynamic profiles of the active components of Shengmai injection, providing valuable information for drug development and clinical application of Shengmai injection.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Chai, H., Q. Wang, L. Huang, T. Xie, and Y. Fu. 2008. Ginsenoside Rb1 inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Biological & Pharmaceutical Bulletin 31: 2050–2056.
Checker, R., R.S. Patwardhan, D. Sharma, J. Menon, M. Thoh, H.N. Bhilwade, T. Konishi, and S.K. Sandur. 2012. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-kappaB. Free Radical Biology & Medicine 53: 1421–1430.
Chen, J., Y. Yao, H. Chen, and J.S. Kwong. 2012. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database of Systematic Reviews 11: CD005052.
Cheung, L.W., K.W. Leung, C.K. Wong, R.N. Wong, and A.S. Wong. 2011. Ginsenoside-Rg1 induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fibroblast growth factor receptor-1. Cardiovascular Research 89: 419–425.
Chiu, P.Y., K.F. Luk, H.Y. Leung, K.M. Ng, and K.M. Ko. 2008. Schisandrin B stereoisomers protect against hypoxia/reoxygenation-induced apoptosis and inhibit associated changes in Ca2+-induced mitochondrial permeability transition and mitochondrial membrane potential in H9c2 cardiomyocytes. Life Sciences 82: 1092–1101.
Deng, G.F., D.L. Wang, M.X. Meng, F. Hu, and T.W. Yao. 2009. Simultaneous determination of notoginsenoside R1, ginsenoside Rg1, Re, Rb1 and icariin in rat plasma by ultra-performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 877: 2113–2122.
Feng, L., L. Wang, C. Hu, and X. Jiang. 2010. Pharmacokinetics, tissue distribution, metabolism, and excretion of ginsenoside Rg1 in rats. Archives of Pharmacal Research 33: 1975–1984.
Gao, Y., J. Deng, X.F. Yu, D.L. Yang, Q.H. Gong, and X.N. Huang. 2011. Ginsenoside Rg1 inhibits vascular intimal hyperplasia in balloon-injured rat carotid artery by down-regulation of extracellular signal-regulated kinase 2. Journal of Ethnopharmacology 138: 472–478.
Gui, F.J., X.W. Yang, L.Y. Li, and J.M. Tian. 2007. Simultaneous enantiomer determination of 20 (R)- and 20 (S)-ginsenoside-Rg2 in rat plasma after intravenous administration using HPLC method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 850: 1–6.
Guo, L.Y., T.M. Hung, K.H. Bae, E.M. Shin, H.Y. Zhou, Y.N. Hong, S.S. Kang, H.P. Kim, and Y.S. Kim. 2008. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. European Journal of Pharmacology 591: 293–299.
Hao, H., L. Lai, C. Zheng, Q. Wang, G. Yu, X. Zhou, L. Wu, P. Gong, and G. Wang. 2010. Microsomal cytochrome p450-mediated metabolism of protopanaxatriol ginsenosides: metabolite profile, reaction phenotyping, and structure–metabolism relationship. Drug Metabolism and Disposition 38: 1731–1739.
Huang, Y.C., C.T. Chen, S.C. Chen, P.H. Lai, H.C. Liang, Y. Chang, L.C. Yu, and H.W. Sung. 2005. A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration. Pharmaceutical Research 22: 636–646.
Huang, Y.L., J.P. Kou, L. Ma, J.X. Song, and B.Y. Yu. 2008. Possible mechanism of the anti-inflammatory activity of ruscogenin: Role of intercellular adhesion molecule-1 and nuclear factor-kappaB. Journal of Pharmacological Sciences 108: 198–205.
Kim, U., M.H. Park, D.H. Kim, and H.H. Yoo. 2013. Metabolite profiling of ginsenoside Re in rat urine and faeces after oral administration. Food Chemistry 136: 1364–1369.
Kou, J., Y. Tian, Y. Tang, J. Yan, and B. Yu. 2006. Antithrombotic activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents. Biological & Pharmaceutical Bulletin 29: 1267–1270.
Li, J., Z.H. Shao, J.T. Xie, C.Z. Wang, S. Ramachandran, J.J. Yin, H. Aung, C.Q. Li, G. Qin, T. Vanden Hoek, and C.S. Yuan. 2012. The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Archives of Pharmacal Research 35: 1259–1267.
Li, L., Y. Sheng, J. Zhang, C. Wang, and D. Guo. 2004a. HPLC determination of four active saponins from Panax notoginseng in rat serum and its application to pharmacokinetic studies. Biomedical Chromatography 18: 849–856.
Li, L., J.L. Zhang, Y.X. Sheng, G. Ye, H.Z. Guo, and D.A. Guo. 2004b. Liquid chromatographic method for determination of four active saponins from Panax notoginseng in rat urine using solid-phase extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 808: 177–183.
Li, X., J. Sun, G. Wang, H. Hao, Y. Liang, Y. Zheng, B. Yan, and L. Sheng. 2007a. Simultaneous determination of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ESI/MS: Platform for the pharmacokinetic evaluation of total panax notoginsenoside, a typical kind of multiple constituent traditional Chinese medicine. Biomedical Chromatography 21: 735–746.
Li, X., G. Wang, J. Sun, H. Hao, Y. Xiong, B. Yan, Y. Zheng, and L. Sheng. 2007b. Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional Chinese medicine (TCM) in rats. Biological & Pharmaceutical Bulletin 30: 847–851.
Liu, H., J. Yang, F. Du, X. Gao, X. Ma, Y. Huang, F. Xu, W. Niu, F. Wang, Y. Mao, Y. Sun, T. Lu, C. Liu, B. Zhang, and C. Li. 2009. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metabolism and Disposition 37: 2290–2298.
Liu, Z.L., Z.J. Liu, J.P. Liu, and J.S. Kwong. 2012. Herbal medicines for viral myocarditis. Cochrane Database of Systematic Reviews 11: CD003711.
Lu, Y., and D.F. Chen. 2009. Analysis of Schisandra chinensis and Schisandra sphenanthera. Journal of Chromatography A 1216: 1980–1990.
Qian, J., F. Jiang, B. Wang, Y. Yu, X. Zhang, Z. Yin, and C. Liu. 2010. Ophiopogonin D prevents H2O2-induced injury in primary human umbilical vein endothelial cells. Journal of Ethnopharmacology 128: 438–445.
Qian, T., Z.H. Jiang, and Z. Cai. 2006. High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Analytical Biochemistry 352: 87–96.
Sun, D., B. Wang, M. Shi, Y.X. Zhang, L.F. Zhou, Z.R. Liu, Z.L. Wu, W. Jiang, J.L. Han, L.Z. Xiong, and G. Zhao. 2012. Pharmacokinetic, tissue distribution and excretion of ginsenoside-Rd in rodents. Phytomedicine 19: 369–373.
Sun, J., G. Wang, X. Haitang, L. Hao, P. Guoyu, and I. Tucker. 2005. Simultaneous rapid quantification of ginsenoside Rg1 and its secondary glycoside Rh1 and aglycone protopanaxatriol in rat plasma by liquid chromatography–mass spectrometry after solid-phase extraction. Journal of Pharmaceutical and Biomedical Analysis 38: 126–132.
Sun, J., W. Wu, Y. Guo, Q. Qin, and S. Liu. 2013. Pharmacokinetic study of ginsenoside Rc and simultaneous determination of its metabolites in rats using RRLC-Q-TOF-MS. Journal of Pharmaceutical and Biomedical Analysis 88C: 16–21.
Wang, C.Z., K.E. Kim, G.J. Du, L.W. Qi, X.D. Wen, P. Li, B.A. Bauer, M.B. Bissonnette, M.W. Musch, E.B. Chang, and C.S. Yuan. 2011. Ultra-performance liquid chromatography and time-of-flight mass spectrometry analysis of ginsenoside metabolites in human plasma. The American Journal of Chinese Medicine 39: 1161–1171.
Wang, L., Y. Zhang, Z. Wang, S. Li, G. Min, J. Chen, J. Cheng, and Y. Wu. 2012. Inhibitory effect of ginsenoside-Rd on carrageenan-induced inflammation in rats. Canadian Journal of Physiology and Pharmacology 90: 229–236.
Wang, W., G.J. Wang, H.T. Xie, J.G. Sun, S. Zhao, X.L. Jiang, H. Li, H. Lv, M.J. Xu, and R. Wang. 2007. Determination of ginsenoside Rd in dog plasma by liquid chromatography-mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 852: 8–14.
Xia, C., G. Wang, J. Sun, H. Hao, Y. Xiong, S. Gu, L. Shang, and C. Zheng. 2008. Simultaneous determination of ginsenoside Rg1, Re, Rd, Rb1 and ophiopogonin D in rat plasma by liquid chromatography/electrospray ionization mass spectrometric method and its application to pharmacokinetic study of ‘SHENMAI’ injection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 862: 72–78.
Xie, J.T., Z.H. Shao, T.L. Vanden Hoek, W.T. Chang, J. Li, S. Mehendale, C.Z. Wang, C.W. Hsu, L.B. Becker, J.J. Yin, and C.S. Yuan. 2006. Antioxidant effects of ginsenoside Re in cardiomyocytes. European Journal of Pharmacology 532: 201–207.
Xu, Q.F., X.L. Fang, and D.F. Chen. 2003. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. Journal of Ethnopharmacology 84: 187–192.
Yang, L., Y. Deng, S. Xu, and X. Zeng. 2007. In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 854: 77–84.
Yang, L., S. Xu, C. Liu, and Z. Su. 2009a. In vivo metabolism study of ginsenoside Re in rat using high-performance liquid chromatography coupled with tandem mass spectrometry. Analytical and Bioanalytical Chemistry 395: 1441–1451.
Yang, L., S.J. Xu, Z.F. Wu, Y.M. Liu, and X. Zeng. 2009b. Determination of ginsenoside-Rg(1) in human plasma and its application to pharmacokinetic studies following intravenous administration of ‘Shenmai’ injection. Phytotherapy Research 23: 65–71.
Zeng, X., Y. Deng, Y. Feng, Y. Liu, L. Yang, Y. Huang, J. Sun, W. Liang, and Y. Guan. 2010. Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers. Journal of Clinical Pharmacology 50: 285–292.
Zhang, S., J. Deng, Y. Gao, D.L. Yang, Q.H. Gong, and X.N. Huang. 2012. Ginsenoside Rb(1) inhibits the carotid neointimal hyperplasia induced by balloon injury in rats via suppressing the phenotype modulation of vascular smooth muscle cells. European Journal of Pharmacology 685: 126–132.
Zhao, J., C. Su, C. Yang, M. Liu, L. Tang, W. Su, and Z. Liu. 2012. Determination of ginsenosides Rb1, Rb2, and Rb3 in rat plasma by a rapid and sensitive liquid chromatography–tandem mass spectrometry method: Application in a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 64–65: 94–97.
Zheng, C., H. Hao, X. Wang, X. Wu, G. Wang, G. Sang, Y. Liang, L. Xie, C. Xia, and X. Yao. 2009. Diagnostic fragment-ion-based extension strategy for rapid screening and identification of serial components of homologous families contained in traditional Chinese medicine prescription using high-resolution LC-ESI-IT-TOF/MS: Shengmai injection as an example. Journal of Mass Spectrometry 44: 230–244.
Zheng, H., Y. Chen, J. Chen, J. Kwong, and W. Xiong. 2011. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database of Systematic Reviews 2: CD005052.
Zhou, D., L. Tong, M. Wan, G. Wang, Z. Ye, Z. Wang, and R. Lin. 2011. An LC–MS method for simultaneous determination of nine ginsenosides in rat plasma and its application in pharmacokinetic study. Biomedical Chromatography 25: 720–726.
Zhu, D., L. Wu, C.R. Li, X.W. Wang, Y.J. Ma, Z.Y. Zhong, H.B. Zhao, J. Cui, S.F. Xun, X.L. Huang, Z. Zhou, and S.Q. Wang. 2009. Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. Journal of Cellular Biochemistry 108: 117–124.
This work was financially supported by the National Basic Research Program of China (No. 2012CB518405) and the Natural Science Foundation of China (No. 81373893).
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Zhan, SY., Shao, Q., Fan, XH. et al. Tissue distribution and excretion of herbal components after intravenous administration of a Chinese medicine (Shengmai injection) in rat. Arch. Pharm. Res. (2014). https://doi.org/10.1007/s12272-014-0376-7
- Tissue distribution
- Shengmai injection